×
AC Immune Net Current Debt 2016-2025 | ACIU
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
AC Immune net current debt from 2016 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
View More
AC Immune Net Current Debt 2016-2025 | ACIU
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
AC Immune net current debt from 2016 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$249.5B
Amgen (AMGN)
$159.2B
Gilead Sciences (GILD)
$144.1B
Vertex Pharmaceuticals (VRTX)
$101.9B
Bristol Myers Squibb (BMY)
$98.6B
GSK (GSK)
$81.7B
CSL (CSLLY)
$69.9B
Regeneron Pharmaceuticals (REGN)
$63.4B
Alnylam Pharmaceuticals (ALNY)
$61.3B
Argenex SE (ARGX)
$40.6B
Insmed (INSM)
$28B
BioNTech SE (BNTX)
$26.6B
Royalty Pharma (RPRX)
$21.2B
Biogen (BIIB)
$20.4B
Incyte (INCY)
$16.9B
Genmab (GNMSF)
$16.1B
Genmab (GMAB)
$15.7B
Illumina (ILMN)
$15.3B
Ascendis Pharma (ASND)
$11.8B
BioMarin Pharmaceutical (BMRN)
$11.2B
QIAGEN (QGEN)
$10.9B
Exelixis (EXEL)
$10.4B
Swedish Orphan Biovitrum (BIOVF)
$10.3B
Moderna (MRNA)
$10.2B
Verona Pharma American Depositary Share (VRNA)
$9B
Exact Sciences (EXAS)
$8.8B
Bio-Techne Corp (TECH)
$8.5B
Halozyme Therapeutics (HALO)
$8.4B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$8B